ID   FTC-238
AC   CVCL_2447
SY   FTC238
DR   CLO; CLO_0003403
DR   CLDB; cl1400
DR   CLDB; cl1401
DR   AddexBio; C0025001/38
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03470981
DR   BioSample; SAMN10987981
DR   cancercelllines; CVCL_2447
DR   Cell_Model_Passport; SIDM00228
DR   Cosmic; 1239978
DR   DepMap; ACH-000897
DR   ECACC; 94060902
DR   GEO; GSM827316
DR   IARC_TP53; 27013
DR   ICLC; HTL96003
DR   LiGeA; CCLE_558
DR   LINCS_LDP; LCL-1678
DR   PharmacoDB; FTC238_369_2019
DR   Progenetix; CVCL_2447
DR   TOKU-E; 4078
DR   Wikidata; Q54835219
RX   PubMed=1384245;
RX   PubMed=14522906;
RX   PubMed=20215515;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=29066502;
RX   PubMed=30737244;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Characteristics: Highly invasive.
CC   Characteristics: Has a near-homozygous genome (NHG) (PubMed=29066502).
CC   HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI) (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1045fs (c.3135delG); Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000126824; Zygosity=Homozygous (PubMed=30737244; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=14522906; PubMed=30737244).
CC   Omics: Deep exome analysis.
CC   Omics: Mitochondrial genome sequenced.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.72%; Native American=2.05%; East Asian, North=2%; East Asian, South=0%; South Asian=0%; European, North=60.8%; European, South=33.42% (PubMed=30894373).
CC   Misspelling: CFT-238; PubMed=1384245; Note=In the French and Spanish abstracts where the abbreviation 'FTC' was translated to 'CFT' and thus also the cell line names.
CC   Derived from site: Metastatic; Lung; UBERON=UBERON_0002048.
ST   Source(s): ECACC; PubMed=25877200; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 11,12
ST   D19S433: 13
ST   D21S11: 32.2
ST   D2S1338: 20
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 10
ST   FGA: 21
ST   Penta D: 12
ST   Penta E: 13
ST   TH01: 9.3
ST   TPOX: 9
ST   vWA: 15,18
DI   NCIt; C8054; Thyroid gland follicular carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1219 ! FTC-133
OI   CVCL_2446 ! FTC-236
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   PubMed=1384245; DOI=10.1007/BF02067383;
RA   Demeure M.J., Damsky C.H., Elfman F., Goretzki P.E., Wong M.G.,
RA   Clark O.H.;
RT   "Invasion by cultured human follicular thyroid cancer correlates with
RT   increased beta 1 integrins and production of proteases.";
RL   World J. Surg. 16:770-776(1992).
//
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29066502; DOI=10.1530/ERC-17-0288;
RA   Corver W.E., Demmers J., Oosting J., Sahraeian S., Boot A., Ruano D.,
RA   van Wezel T., Morreau H.;
RT   "ROS-induced near-homozygous genomes in thyroid cancer.";
RL   Endocr. Relat. Cancer 25:83-97(2018).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//